



Contact:

Douglas Doerfler
Chief Executive Officer
MaxCyte, Inc.
(301) 944-1700

For Immediate Release

MaxCyte Announces Appointment of Stanley Erck to Board of Directors

Gaithersburg, MD, April 19, 2005 – MaxCyte, Inc., a clinical stage therapeutic company and pioneer in non-viral, closed, clinical scale cell loading systems, announces the appointment of Stanley Erck to its Board of Directors. Mr. Erck is President, CEO, and Director of IOMAI Corporation, a company pioneering the successful delivery of vaccines and immunostimulants to the skin, located in Gaithersburg, Maryland.

Commenting on Mr. Erck's appointment MaxCyte's President and CEO Doug Doerfler said, "Stan's wealth of experience in both the capital markets and pioneering new approaches to improving the delivery of therapeutics will be a powerful addition to MaxCyte's Board. I am thrilled to be working with Stan and look forward to his contributions as a Board member of MaxCyte."

"MaxCyte has a unique approach that will allow important therapeutic products to be commercialized" said Stan Erck. "They've assembled a great team, brought their first product into human trials and have uniquely broad opportunities for commercial success. It's great to become part of the MaxCyte team."

Mr. Erck applies his 25 years of management experience in the healthcare and biotechnology industry (Baxter International, Procept and Integrated Genetics) to shepherd the development and commercialization of IOMAI technology. In addition to successfully negotiating major alliances with pharmaceutical and biotechnology companies and bringing products into clinical trials, as CEO he has managed the process of developing companies from private funding through IPO. Mr. Erck received his B.S. from the University of Illinois and an M.B.A. from the University of Chicago.

About MaxCyte

MaxCyte is a clinical stage therapeutics company developing both proprietary and partnered therapeutics. The company's mission is to use its proprietary cell-loading technology to advance its therapeutic programs and enable other developers of *ex vivo* cell therapies and manufacturers of biopharmaceutical products and therapies. MaxCyte's strength is its ability to accelerate development timelines and reduce risk in bringing cell and gene therapies from bench to a clinical reality. MaxCyte's proprietary cell loading technology is closed and scalable, highly efficient, reproducible and reduces regulatory risk in *ex vivo* cell loading. MaxCyte's pipeline includes one product in Phase I/II clinical trials for the treatment of Chronic Lymphocytic Leukemia (CLL) and several preclinical candidates to treat a variety of diseases with unmet needs. Therapeutic applications include non-viral gene delivery and delivery of a therapeutic drug or large proteins; current partners are working to develop therapeutics for pulmonary, infectious and genetic disease, and oncology. MaxCyte's technology for biotherapeutic manufacturing allows the scalable production of viral vectors, making possible all phases of the development process, from pre-

clinical through clinical trials and through to product manufacturing. Cell-loading technologies are fundamental to cell-based therapeutics, gene therapy, and many biopharmaceutical manufacturing applications. MaxCyte has developed and commercialized the most efficient non-viral, clinical grade, scalable, GMP-compliant cell-loading technology in the marketplace.

For more information, visit <http://www.maxcyte.com>.

This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.

###